Modality
mAb
MOA
RAS(ON)i
Target
IL-13
Pathway
Sphingolipid
FSGSNMOSD
Development Pipeline
Preclinical
~Oct 2022
→ ~Jan 2024
Phase 1
Apr 2024
→ Dec 2029
Phase 1Current
NCT06930019
1,446 pts·NMOSD
2024-04→2029-12·Completed
NCT03513600
2,689 pts·NMOSD
2024-08→2026-09·Recruiting
4,135 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-09-045mo awayPh2 Data· NMOSD
2029-12-103.7y awayPh2 Data· NMOSD
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Complet…
P1/2
Recruit…
Catalysts
Ph2 Data
2026-09-04 · 5mo away
NMOSD
Ph2 Data
2029-12-10 · 3.7y away
NMOSD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06930019 | Phase 1/2 | NMOSD | Completed | 1446 | DAS28 |
| NCT03513600 | Phase 1/2 | NMOSD | Recruiting | 2689 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 |